bullish
Keymed Biosciences (2162.HK) - Behind the Plunge in Share Price and the Outlook
353 Views30 May 2023 08:55
The share price plunge shows there's either a low-level mistake or "other issues", which may have a negative impact on the whole ecology of HKEX. We still think CX310 will ultimately launch on market.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Sinopharm Group (1099.HK) - Performance Pressure May Continue Until 2024H128 Dec 2023
- Keymed Biosciences (2162.HK) - Looking Forward to the Next Leap in Valuation15 Nov 2023
- China Healthcare Weekly (Jun.2) - New Era for Medical Device, Shareholders' Reduction in CXO, Cstone04 Jun 2023
- Keymed Biosciences (2162.HK) - Behind the Plunge in Share Price and the Outlook30 May 2023
- Keymed Biosciences (2162.HK) - The $1.2B Deal with AstraZeneca for ADC and the Logic Behind28 Feb 2023
- Keymed Biosciences (2162.HK) - We Have High Hopes for Keymed, but Valuation Is Expensive21 Feb 2023
- Keymed Biosciences (2162.HK) - The Potential for Doubling Valuation and the Corresponding Risks20 Jun 2022
x